Literature DB >> 21099725

Prednisolone in Bell's palsy related to treatment start and age.

Sara Axelsson1, Thomas Berg, Lars Jonsson, Mats Engström, Mervi Kanerva, Anne Pitkäranta, Anna Stjernquist-Desatnik.   

Abstract

OBJECTIVE: To evaluate if treatment start and age are related to the outcome in Bell's palsy patients treated with prednisolone. STUDY
DESIGN: Prospective, randomized, double-blind, placebo-controlled, multicenter trial.
SETTING: Sixteen otorhinolaryngologic centers in Sweden and 1 in Finland. PATIENTS: Data were collected from the Scandinavian Bell's palsy study. A total of 829 patients were treated within 72 hours of onset of palsy. Follow-up was 12 months. INTERVENTION: Patients were randomly assigned to treatment with placebo plus placebo (n = 206), prednisolone plus placebo (n = 210), valacyclovir plus placebo (n = 207), or prednisolone plus valacyclovir (n = 206). MAIN OUTCOME MEASURES: Facial function was assessed with the Sunnybrook grading system, and complete recovery was defined as Sunnybrook = 100. Time from onset of palsy to treatment start was registered.
RESULTS: Patients treated with prednisolone within 24 hours and 25 to 48 hours had significantly higher complete recovery rates, 66% (103/156) and 76% (128/168), than patients given no prednisolone, 51% (77/152) and 58% (102/177) (p = 0.008 and p = 0.0003, respectively). For patients treated within 49 to 72 hours of palsy onset, there were no significant differences. Patients aged 40 years or older had significantly higher complete recovery rates if treated with prednisolone, whereas patients aged younger than 40 years did not differ with respect to prednisolone treatment. However, synkinesis was significantly less in patients younger than 40 years given prednisolone (p = 0.002).
CONCLUSION: Treatment with prednisolone within 48 hours of onset of palsy resulted in significantly higher complete recovery rates and less synkinesis compared with no prednisolone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21099725     DOI: 10.1097/MAO.0b013e3182009f35

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Management of Bell palsy: clinical practice guideline.

Authors:  John R de Almeida; Gordon H Guyatt; Sachin Sud; Joanne Dorion; Michael D Hill; Michael R Kolber; Jane Lea; Sylvia Loong Reg; Balvinder K Somogyi; Brian D Westerberg; Chris White; Joseph M Chen
Journal:  CMAJ       Date:  2014-06-16       Impact factor: 8.262

2.  The Importance of the Neutrophil-Lymphocyte Ratio in Patients with Idiopathic Peripheral Facial Palsy.

Authors:  M Mustafa Kiliçkaya; Mustafa Tuz; Murat Yariktaş; Hasan Yasan; Giray Aynalı; Özkan Bagci
Journal:  Int J Otolaryngol       Date:  2015-12-02

Review 3.  Role of Biomarkers as Prognostic Factors in Acute Peripheral Facial Palsy.

Authors:  Tae Hoon Kim; Seung Geun Yeo; Jae Yong Byun
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

4.  Early intervention with acupuncture improves the outcome of patients with Bell's palsy: A propensity score-matching analysis.

Authors:  Lian-Sheng Yang; Dan-Feng Zhou; Shu-Zhen Zheng; Bai-Ming Zhao; Huo-Gui Li; Qi-Qing Chen; Yun Zhong; Hong-Zhi Yang; Kun Zhang; Chun-Zhi Tang
Journal:  Front Neurol       Date:  2022-09-14       Impact factor: 4.086

5.  Effects of electroacupuncture therapy for Bell's palsy from acute stage: study protocol for a randomized controlled trial.

Authors:  Zhi-dan Liu; Jiang-bo He; Si-si Guo; Zhi-xin Yang; Jun Shen; Xiao-yan Li; Wei Liang; Wei-dong Shen
Journal:  Trials       Date:  2015-08-25       Impact factor: 2.279

6.  Advances in diagnosis and non-surgical treatment of Bell's palsy.

Authors:  Yang Zhao; Guodong Feng; Zhiqiang Gao
Journal:  J Otol       Date:  2015-06-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.